Focused therapeutic areas and pipeline progress

Cancer has affected people of all ages and societies throughout human history, posing a serious threat to life. Addressing this multifaceted global health issue stands as one of the most pressing challenges and missions in modern biomedical science.

mRNA-based therapeutics in cancer treatment induce antigen expression, which triggers strong, specific immune responses, enabling multiple precise and effective immuno-oncology therapies. Dedicated to immuno-oncology and driven by innovation, we strive to bring hope to cancer patients globally.

mRNA therapy can deliver mRNA molecules encoding specific therapeutic proteins to the body, enabling cells to encode and produce therapeutic antibodies or to supplement or replace the absence or abnormal function of proteins, thereby treating diseases.

Our protein replacement programs can instruct human cells to encode various peptides, proteins and antibodies, to enhance target protein expression or to substitute current antibody therapies and address certain inherent issues found in certain antibodies, thereby treating diseases.

For centuries, the epic of humanity’s fight against infectious diseases has been marked by wisdom, resilience and scientific progress. The outbreak of COVID-19 pandemic further accelerated advancements in vaccine technology, with mRNA vaccines emerging as novel and effective tools with strong immune responses, remarkable speed and efficacy.

With the aspiration to safeguard global health, we have developed a diverse product pipeline covering varicella zoster virus (“VZV”), respiratory syncytial virus (“RSV”) and tuberculosis (“TB”).